ValuEngine upgraded shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning.

Several other research analysts have also weighed in on VBLT. Zacks Investment Research raised shares of Vascular Biogenics from a sell rating to a hold rating in a report on Wednesday, July 19th. HC Wainwright set a $11.00 price objective on shares of Vascular Biogenics and gave the stock a buy rating in a report on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $12.90.

Vascular Biogenics (NASDAQ VBLT) opened at 6.15 on Wednesday. The firm’s market cap is $166.11 million. Vascular Biogenics has a 52 week low of $3.90 and a 52 week high of $7.25. The company’s 50 day moving average is $4.93 and its 200-day moving average is $5.16.

Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. Equities analysts expect that Vascular Biogenics will post ($0.74) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/23/vascular-biogenics-ltd-vblt-upgraded-by-valuengine-to-hold.html.

A hedge fund recently raised its stake in Vascular Biogenics stock. Menta Capital LLC grew its stake in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) by 5.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,935 shares of the biopharmaceutical company’s stock after acquiring an additional 6,200 shares during the period. Menta Capital LLC owned about 0.45% of Vascular Biogenics worth $671,000 at the end of the most recent quarter. 11.28% of the stock is currently owned by institutional investors and hedge funds.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.